Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OAT | P04181 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gabaculine SCHEMBL6237522 | 1.00 | OAT (1.00) | OATTSHRMAPK1HSD17B10TDP1 | |
| Gabaculine SCHEMBL22691967 | 1.00 | OAT (1.00) | OATTSHRMAPK1HSD17B10TDP1 | |
| Gabaculine SCHEMBL23142324 | 0.98 | OAT (0.96) | OATTSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL30782573 | 0.87 | — | — | |
| SCHEMBL23144983 | 0.87 | — | — | |
| SCHEMBL23142323 | 0.77 | OAT (0.62) | OATTSHRMAPK1HSD17B10THRB | |
| SCHEMBL23622833 | 0.77 | OAT (0.62) | OATTSHRMAPK1HSD17B10THRB | |
| SCHEMBL23622807 | 0.77 | OAT (0.62) | OATTSHRMAPK1HSD17B10THRB | |
| SCHEMBL6518383 | 0.77 | OAT (0.62) | OATTSHRMAPK1HSD17B10TDP1 | |
| SCHEMBL25918222 | 0.77 | OAT (0.62) | OATTSHRMAPK1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4620463-A1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON - Skin & Hair Innovations GmbH (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250081908-A1 | MICROALGAE-BASED SOIL INOCULATING SYSTEM AND METHODS OF USE | PACEZERO SUSTAINABLE CREDIT FUND II (CA) | 2025-03-13 | — | — | US | disclosed |
| US-20230321122-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION | CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) | 2023-10-12 | — | — | US | disclosed |
| EP-3766545-B1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON SKIN & HAIR INNOVATIONS GMBH (DE) | 2023-08-16 | — | — | EP | disclosed |
| US-20220168206-A1 | ACTIVE AGENT FOR USE IN HAIR GROWTH REGULATION | CUTANEON - SKIN & HAIR INNOVATIONS GMBH (DE) | 2022-06-02 | — | — | US | disclosed |
| WO-2022043171-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION | MONASTERIUM LABORATORY SKIN & HAIR RESEARCH SOLUTIONS GMBH (DE) | 2022-03-03 | — | — | WO | disclosed |
| EP-3960150-A1 | ACTIVE AGENT MODULATING THE ACTIVITY OF AN ION CHANNEL FOR USE IN HAIR GROWTH REGULATION | Monasterium Laboratory Skin & Hair Research Solutions GmbH (DE) | 2022-03-02 | — | — | EP | disclosed |
| US-20210206714-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206714-A1 | COMPOSITIONS AND METHODS FOR REDUCING TACTILE DYSFUNCTION, ANXIETY, AND SOCIAL IMPAIRMENT | PMP22, GABBR1, GABBR2 | OAT 421/4885TSHR 3757/4885MAPK1 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.